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Percutaneous Intracoronary Cellular Cardiomyoplasty for Nonischemic Cardiomyopathy:
Clinical and Histopathological Results: The First-in-Man ABCD
(Autologous Bone Marrow Cells in Dilated Cardiomyopathy) Trial
To the Editor: Stem cell therapy has shown potential benefit in
heart failure caused by ischemic heart disease (1). There is no data
on the role of stem cell therapy in nonischemic dilated cardiomy-
opathy. We undertook a pilot study of intracoronary stem cell
implantation in patients with dilated cardiomyopathy.
From a cohort of 44 patients, 24 were randomly allocated to the
stem cell therapy arm and 20 to the control arm. All patients were
having dilated cardiomyopathy with an ejection fraction (EF) of
35%, were New York Heart Association (NYHA) functional
class II or more symptomatic for more than 6 months, had normal
coronary arteries, and had no other comorbidities such as chronic
renal or liver failure or any malignancy.
Patients in the treatment arm underwent bone marrow aspira-
tion (50 to 60 ml) from the iliac crest. Mononuclear cells were
separated from the bone marrow using Ficoll density gradient
separation. The mononuclear cells constituted 89  2% of the
cells, were 28  16 million /ml, and CD 34 cells were 1.6
million/ml. The viability of these cells was 99  1%. The patients
then underwent right heart catheterization and endomyocardial
biopsy from the right side of the interventricular septum. The
coronary sinus was then engaged using a Swan-Ganz catheter
(Arrow International, Reading, Pennsylvania) that was passed up
the coronary sinus, and the balloon was inflated. This was done so
that the coronary circulation was slowed and the stem cells would
get more time to transmigrate into the myocardium. Once the
coronary sinus catheter was inflated, the stem cells were slowly
injected into the coronary arteries by hooking the arteries with a
Judkins catheter. Two-thirds of the mononuclear cell concentrate
was injected into the left coronary artery and one-third was
injected into the right coronary artery. The coronary sinus balloon
was kept inflated for 3 min during the intracoronary injection. The
patients were kept under monitoring for 24 h with electrocardio-
graphic monitoring and serial cardiac enzymes. Follow-up was
done at 1 week, 1 month, and then every 3 months for 1 year. At
3 months, Holter monitoring, an echocardiogram, and an endo-
myocardial biopsy were repeated. An echocardiogram was also
repeated at 1 year. Left ventricular function assessment was
performed offline by the modified Simpson method by 2 observers
blinded to the underlying treatment. All patients were on the
maximum tolerated doses of angiotensin-converting enzyme in-
hibitors and beta-blockers. Diuretic doses (including frusemide
and torsemide, and spironolactone) were adjusted to ensure the
absence of pedal edema. Informed consent was obtained from all
patients, including control patients. The end points of the study
were: 1) change in NYHA functional class, 2) a change in left
ventricular function, 3) mortality, and 4) endomyocardial biopsy
and histopathologic evaluation.
Continuous variables were compared by a Wilcoxon 2-sample
test (for within-group differences) and the Mann-Whitney U test
(between-group differences). Differences in mortality and change
in functional class between the 2 groups were compared by the
Fisher exact test. A value of p  0.05 was considered statistically
significant. All analyses were performed with SPSS for Windows
(version 10.0.1, 1999, SPSS Inc., Chicago, Illinois).
The data of the analysis at 6 months are presented. Four
patients died between 1 and 3 months in the treatment arm. Three
died of progressive heart failure and 1 experienced sudden cardiac
death. The mortality was not significantly different (p value not
significant) between the treatment and control (2 patients died)
arms.
There was a significant improvement (p  0.001) in NYHA
functional class in the treatment arm, with 16 patients (62%)
improving by at least 1 functional class, as compared with only 2
patients (10%) improving in the control arm.
The EF improved by 5.4% (20  7.4% to 25  12%, p  0.05)
(Fig. 1) with a reduction in end-systolic volumes (144  85 ml to
116  68 ml, p  0.05) and no change in end-diastolic volumes.
None of the patients who were functional class IV and had recently
required inotropic infusions showed any improvement. There was
no significant improvement in the EF in the control arm (baseline
EF  16  5.4% to final EF  16  4.7%).
Endomyocardial biopsy was performed at 3 months. Histopa-
thology revealed no evidence of persisting stem cells, no evidence
of any new immature myocytes, and also no evidence of any
inflammation, infarction, or neovascularization.
Two patients had scattered binucleate cells and evidence of cell
proliferation (Ki 67/MIB 1 [M7240; Dako stain positive cells,
Dako, Glostrup, Denmark]). Morphometric analysis (Image Pro
Plus software with 20 magnification, version 4.1, 1999, Media
Cybernetics Inc., Silver Spring, Maryland) showed no change in
the absolute number of myocytes (457  210 cells/mm2 [before]
and 340 150 cells/mm2 [after]). There was also no change in the
number of capillary endothelial cells (stained by CD34 class II, 696
 206 cells/mm2 [before] and 569  150 cells/mm2 [after]). The
ratio of capillaries to myocytes showed an increase, but it was not
significant (1.7  0.7 to 1.9  0.8). There was no significant
Figure 1. Change in ejection fraction (EF) after 6 months of follow-up.
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difference between the mortality in the treatment (16.7%) and
control (10%) arms. In the control group, 2 patients died. There
was no significant change in functional class or left ventricular
function in this group.
In summary, 24 patients underwent intracoronary stem cell
injection with coronary sinus blockage. Four patients died during
the 6-month follow-up. Overall EF showed a small but significant
improvement of 5.4%. There was a decrease in end-systolic
volumes, but no change in end-diastolic volumes. Endomyocardial
biopsy done at 3 months showed no significant change in the
number of myocytes or capillaries, but the ratio of capillaries to
myocytes showed an insignificant increase. There were soft data to
suggest cell proliferation (binucleate cells and Ki 67 positivity).
This is the first study of stem cell therapy in dilated nonischemic
cardiomyopathy. Over a 6-month period, there was a small albeit
significant improvement in ventricular function. Previous clinical
studies have also shown a small degree of change in ventricular
function of a similar magnitude (1,2). Laboratory experiments in
nonischemic dilated cardiomyopathy (3) have previously suggested
that benefit from stem cell therapy in this group comes mainly
from a decrease in fibrosis and an increase in vascularity, but no
evidence has been found supporting transdifferentiation of stem
cells to myocytes. Our data also suggest that the benefit of stem cell
therapy could be a paracrine effect with changes in vascularity, perhaps
stimulation of cell proliferation, or by some still-unexplored mecha-
nism. We did not find any evidence of transdifferentiation.
In this study we wish to highlight a number of issues. It is the
first study to show the benefit of stem cells in nonischemic dilated
cardiomyopathy, and the first study that uses coronary sinus
occlusion to increase cell contact time. It is also the first study in
which we have endomyocardial biopsies performed after stem cell
therapy.
It provides a stimulus for exploring the benefits of stem cell
therapy in nonischemic dilated cardiomyopathy. A double-blind
study is being planned to further explore the benefit seen in this
preliminary study. The small magnitude of benefit could perhaps
be because all patients in this study were in very late stages of their
cardiomyopathy, and we probably need to consider stem cell
therapy at a much earlier stage. Endomyocardial biopsy, performed
for the first time in stem cell therapy, shows no evidence of
transdifferentiation of stem cells to myocytes but provides soft data
pointing to a possible paracrine effect.
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Are Familial Mediterranean Fever (FMF) Patients at Increased Risk for Atherosclerosis?
Impaired Endothelial Function and Increased Intima Media Thickness Are Found in FMF
To the Editor: Familial Mediterranean fever (FMF) is an auto-
inflammatory disease characterized by periodic attacks of fever and
serositis caused by mutations in FMF gene (MEFV). Although
FMF patients are symptom free between the attacks, subclinical
inflammation continues during the attack-free period (1). Patients
with inflammatory diseases, such as those with systemic lupus
erythematosus and rheumatoid arthritis, are now considered to
have an increased risk of atherosclerotic cardiovascular complica-
tions. Intima media thickness (IMT) of carotid arteries and
endothelial dysfunction are used to define the preclinical athero-
sclerosis (2). We attempted to determine whether FMF patients
have an increased risk of atherosclerosis by assessing endothelium-
dependent flow-mediated dilation (FMD) of brachial artery and
IMT of carotid arteries. We also investigated the association
between these parameters and inflammatory markers.
We studied 43 FMF patients and 29 healthy control subjects.
All FMF patients enrolled in the study fulfilled the clinical criteria
for FMF (3). Patients with diabetes mellitus, hypertension, ath-
erosclerotic vascular disease, malignancy, amyloidosis, active infec-
tious disease, pregnancy, or other inflammatory diseases were
excluded. All subjects had a complete history and physical exam-
ination. Clinical and laboratory assessment of FMF patients were
performed during an attack-free period. The FMF patients unre-
sponsive to colchicine therapy have been previously defined (4).
Erythrocyte sedimentation rate (ESR) and fibrinogen were
measured. Serum glucose and serum lipids were determined by
using an autoanalyzer. Serum amyloid A (SAA) was determined by
a commercial micro– enzyme-linked immunosorbent assay
method, and high-sensitivity C-reactive protein (hs-CRP) was
determined by immunonephelometry. Genetic analysis data of
FMF patients were obtained from hospital file records.
Endothelial function was assessed by FMD from the brachial
artery, and IMT of carotid arteries was measured as previously
described (5,6). The maximum IMT (the highest value of the 6
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